The Zinc Finger Protein GLI1 pipeline drugs market research report outlays comprehensive information on the Zinc Finger Protein GLI1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Zinc Finger Protein GLI1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Musculoskeletal Disorders which include the indications Solid Tumor, Basal Cell Carcinoma (Basal Cell Epithelioma), and Bone Disorders. It also reviews key players involved in Zinc Finger Protein GLI1 targeted therapeutics development with respective active and dormant or discontinued products.
The Zinc Finger Protein GLI1 pipeline targets constitutes close to five molecules. Out of which, approximately three molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 2, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Zinc Finger Protein GLI1 overview
Zinc Finger Protein GLI1 (GLI1) is a member of the Kruppel family of zinc finger proteins. It plays a role in craniofacial development and digital development, as well as development of the central nervous system and gastrointestinal tract. It also plays a role in cell proliferation and differentiation via its role in SHH signaling. GLT1 regulates the transcription of specific genes during normal development.
For a complete picture of Zinc Finger Protein GLI1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
